SteadyMed Therapeutics yesterday set the terms for its pending debut on the public market, saying it plans to float 4.25 million shares at $12 to $14 apiece.
SteadyMed sets terms for $55m IPO
Bellerophon prices $60m IPO low, issues more shares
Diabetes: Intarcia inks $1B development deal with Servier
Intarcia Therapeutics said today that French pharmaceutical independent Servier agreed to a deal to commercialize Intarcia’s implantable diabetes pump that could be worth some $1 billion.
Fresenius ends Russia joint venture, feels impact of Ukraine crisis
Shareholders lawsuit against Unilife fizzles
pSivida gains big on buyout rumor
Shares of ophthalmology company pSivida (NSDQ:PSDV) hit a 52-week high today on speculation from a Seeking Alpha blogger that it’s ripe for an acquisition this year.
PSDV shares hit $3.96 each today, a 52-week high, having gained some 15.5% since a blogger writing as "Bob’s Stocks" published the rumor yesterday.
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn